<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALBENDAZOLE</span><br/>(al-ben'da-zole)<br/><span class="topboxtradename">Albenza<br/></span><b>Classifications:</b> <span class="classification"> antiinfective</span>; <span class="classification">anthelmintic agent</span><br/><b>Prototype: </b>Mebendazole<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Albendazole is a broad-spectrum oral anthelmintic agent. It is the only anthelmintic drug active against all stages of the
         helminth life cycle (ova, larvae, and adult worms). Its mechanism of action is unclear, but it appears to cause selective
         degeneration of cytoplasmic microtubules in the intestinal cells of the helminths and larvae.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Albendazole ultimately causes decreased ATP production in the helminths, resulting in energy depletion, which kills the worms.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of neurocysticercosis caused by the larval form of pork tapeworm (<i>Taenia solium</i>), hydatid disease caused by the larval form of dog tapeworm (<i>Echinococcus granulosus</i>).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to the benzimidazole class of compounds or any components of albendazole; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Retinal lesions, lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Neurocysticercosis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;6 y,</i> weight 60
               kg, 400 mg b.i.d. for 830 d cycle<br/><br/><span class="indicationtitle">Hydatid Disease</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;6 y,</i> weight 60 kg,
               400 mg b.i.d. for 28 d cycle (then 14 d without drug &amp; repeat regimen for 3 cycles)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meals. Absorption is significantly increased with a fatty meal.</li>
<li>Do not exceed maximum total daily dose of 800 mg.</li>
<li>Store at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Hypersensitivity reactions. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, vertigo, increased intracranial pressure, meningeal signs, alopecia (reversible), fever. <span class="typehead">GI:</span>
<span class="speceff-common">Abnormal liver function tests,</span> abdominal pain, nausea, vomiting. <span class="typehead">Hematologic:</span> (Rare) Reversible leukopenia, granulocytopenia, pancytopenia, <span class="speceff-life">agranulocytosis</span>. <span class="typehead">Skin:</span> Rash, urticaria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cimetidine,</b>
<b>dexamethasone,</b>
<b>praziquantel</b> increase albendazole levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract, absorption enhanced with a fatty meal. <span class="typehead">Peak:</span> 25 h. <span class="typehead">Distribution:</span> 70% bound to plasma proteins; widely distributed throughout body including cyst fluid and CSF; secreted into animal breast
      milk. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolite, albendazole sulfoxide. <span class="typehead">Elimination:</span> Excreted in bile. <span class="typehead">Half-Life:</span> 812 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor WBC count, absolute neutrophil count, and liver function tests at start of each 28-d cycle and q2wk during
            cycle.
         </li>
<li>Withhold drug and notify physician if WBC count falls below normal or liver enzymes are elevated.</li>
<li>
            							Note: Patients should be concurrently treated with appropriate steroid and anticonvulsant therapy.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take with meals (see <small>ADMINISTRATION</small>).
         </li>
<li>Do not become pregnant during or for at least 1 mo after therapy.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>